Table 4 Results of the main series of radiotherapy of chordomas of the mobile spine and the sacrum
Beam | # Pts (location) | Dose Gy (RBE) | Dose/Fx Gy (RBE) | Median follow-up (years) | Local control at years | Global non-specific (specific) survival at years | Presence of metastasis | Reference |
|---|---|---|---|---|---|---|---|---|
X | 48: 23 (S) 20 (SB) 5 (MS) | 50/40/24 | 2/1/8 | 54% at 5 | Catton et al. [19] | |||
20% at 10 | ||||||||
X | 26: 12 (S) 10 (SB) 4 (MS) | [30–66.6] | [1.8–2.5] | 62% at 5 | Cummings et al. [20] | |||
(83% at 5) | ||||||||
28% at 10 | ||||||||
X (IMRT) | 34 (S) | 66 | [1.8–2] | 4.5 | 27% at 5 | 70% at 5 | 9% | Zabel-du Bois et al. [21] |
(80% at 5) | ||||||||
X (IMRT) | 7 (MS) | 66 | [1.8–2] | 1.45 | 65% at 2 | Terezakis et al. [22] | ||
X (SRS) | 24: 10 (S) 7 (C) 4 (T) 3 (L) | 18–24 | [18–24] | 2 | 95% at 4 | 67% at 4 | 12.5% | Yamada et al. [23] |
X (SBRT) | 18: 8 (MS) 7 (SB) 3 (S) | 35 | [6–8] | 3.8 | 59.1% at 5 | 74.3% at 5 | Henderson et al. [24] | |
1H +/−X | 29 (MS) | 76.6 | 1.8 | 7.3 | 84% at 5 | 87% at 5 | ||
24: 19 (S) 2 (C) 1 (T) 2 (L) | 77.4 | [1.8–2.5] | 4.7 | 90.4% at 3 79.8% at 5 | 78.1% at 5 | Chen et al. [25] | ||
25 (MS, S) | 70.4 | 1.8 | 2.65 | 73.3% at 5 | 64.3% at 5 | Wagner et al. [26] | ||
26: 9 (C) 2 (T) 8 (L) 7 (S) | 72 | [1.8–2.5] | 2.9 | 86% at 3 | 84% at 3 | Rutz et al. [27] | ||
19: 12 (SB) 5 (C) 1 (L) 1 (S) | 74 | [1.8–2] | 3.8 | 81% at 5 | 89% at 5 | Rombi et al. [28] | ||
40: 16 (C) 4 (T) 10 (L) 11 (S) | 72.5 | [1.8–2] | 3.6 | 62% at 5 | 80% at 5 | Staab et al. [29] | ||
12C | 38 (S) | 70.4 | [4.4–4.6] | 6.7 | 95% at 3 89% at 5 | 95% at 3 | Imai et al. [6] | |
86% at 5 | ||||||||
17 (S) | 70.4 | [4.4–4.6] | 4.1 | 100% at 5 | 53.3% at 5 | 14% | Nishida et al. [30] |